Tumor markers are substances found in blood and other biological fluids if tumor is present in the body. They can be produced by tumor itself or can be results of cancer -body relation. They may be used in the follow-up of cancer patients to identify tumor recurrence. Pre-treatment levels have prognostic tool and could signalize persistence of minimal residual disease despite radical surgery.
Introduction
Gastric cancer is the fourth abundant malignancy worldwide. Even when surgical resection is possible, the longterm survival is observed only in minority of patients with an overall five-year survival less than 30% 1,2 .
The most important prognostic factor influencing survival of patients with stomach cancer is the extent of disease as assessed by tumor stage.
The incidence of pancreatic cancer rises .
Methods
We examined 52 patients with malignant disease (32 with gastric cancer and 20 with pancreatic cancer). There were 19 men and 11 women in group with gastric cancer and 12 men and eight women in group with pancreatic cancer. The average age of the patients in the group with gastric cancer was 67 years (range 37 -87 years), in group with pancreatic cancer was 63 years (range 48 -79 years) ( Table 1) . Comparison of the levels of CEA and Ca 19 -9 in sera and peritoneal lavage in patients suffering from gastric and pancreatic carcinoma was performed. Blood samples were collected after diagnosis of the disease. Peritoneal samples were taken immediately after laparotomy. When ascites was present, 20 ml were sent to biochemistry laboratory. In cases without ascites the peritoneal cavity was lavaged with 100 ml saline solution and the samples were collected 5 minutes later. Levels of the CEA and Ca 19 -9 were examined. Physiological range was the same for peritoneal fluid and sera. CEA ranges were 0 -4, 6 μg/l, Ca 19 -9 levels were normal within 0 -37 U/l.
Patients were stratified according to the stage of the disease.
Results
Tumor markers sensitivity and specificity (Tables 2 and   3) Sensitivity and specificity for microscopic intraperitoneal cancer dissemination were evaluated in group of patient without confirmation of the malignant tumors and in patients with serosal infiltration or serosal metastases (we expected 100% prevalence of tumor cells in the peritoneal fluid in these patients and 100%
positivity of the tumor markers). CEA sensitivity was 38% and Ca 19-9 42%, respectively.
Combination of both markers achieved 53% (we repeatedly found elevation only ones of both markers). Specificity of the biochemistry examination was 100%.
Gastric cancer
CEA levels in sera were within normal ranges in nearly To sum-up, the percentage of negative findings of both markers in sera and peritoneal cavity was decreasing according to the stage of the disease. Positivity of both markers was increasing reversely and Ca 19 -9 was probably more sensitive than CEA ( Figure 4 ). 
Pancreatic carcinoma
Patients with pancreatic carcinoma had normal levels of CEA in stages I and II (except for one patient). Positivity in stage III and IV is much higher. 20 % of patients had elevated levels of CEA in sera and 43 % displayed elevation in the peritoneal cavity ( Figure 5 ). In summary, physiological ranges of both markers were less frequent than in cases of gastric carcinoma. Only 30% of patients had negative finding in sera in stages I and II. Negativity of both markers in higher stages was about 15%. The intraperitoneal finding was similar, but there were more negative patients in stages I and II (Figure 8 ). cytology despite various detection rates [14] [15] [16] [17] [18] .
Positive peritoneal cytology could predict the site of recurrence. It is an independent prognostic factor of the intraperitoneal dissemination (sensitivity 56%, specificity 97%) 19 .
However, the sensitivity and specificity of cytology is very high in Asian countries, nonetheless in the western countries the results are worse. In our previous study we published that cytology had sensitivity only 34% and specificity 80%. 
